It is hot in New Orleans this June, and we don’t mean the temperature... Every year biotech investors eagerly await ASCO, the American Society for Clinical Oncology annual meeting. It is the meeting par excellence for new announcements and scientific presentations regarding clinical trial results. The meeting attracts over 25,000 delegates from all over the world. Since many biotechs are focused on cancer, it is a major meeting for the industry. This year’s meeting is no exception. With so many new cancer drugs in trials, investors are eagerly awaiting news from the clinic.
